Maternal genotype effects can alias case genotype effects in case–control studies

[1]  L. E. Mitchell,et al.  Maternal genotype for the monocyte chemoattractant protein 1 A(‐2518)G promoter polymorphism is associated with the risk of spina bifida in offspring , 2006, American journal of medical genetics. Part A.

[2]  M. McDonnell,et al.  Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. , 2002, American journal of human genetics.

[3]  C. Masimirembwa,et al.  Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants , 1997, Brain Research Bulletin.

[4]  C R Weinberg,et al.  A log-linear approach to case-parent-triad data: assessing effects of disease genes that act either directly or through maternal effects and that may be subject to parental imprinting. , 1998, American journal of human genetics.

[5]  V. Soriano,et al.  Overview of the pharmacogenetics of HIV therapy , 2006, The Pharmacogenomics Journal.

[6]  P. Donnelly,et al.  New models of collaboration in genome-wide association studies: the Genetic Association Information Network , 2007, Nature Genetics.

[7]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[8]  W. Johnson.  Teratogenic alleles and neurodevelopmental disorders. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  R. T. Lie,et al.  Case‐parent Triads: Estimating Single‐ and Double‐dose Effects of Fetal and Maternal Disease Gene Haplotypes , 2006, Annals of human genetics.

[10]  R. Bhopal,et al.  Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century , 2005, Journal of Epidemiology and Community Health.

[11]  J. Kaiser.  Genomic medicine. African-American population biobank proposed. , 2003, Science.

[12]  C. Li,et al.  The Derivation of Joint Distribution and Correlation between Relatives by the Use of Stochastic Matrices , 1954 .

[13]  S. Buyske,et al.  Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. , 2007, Archives of pediatrics & adolescent medicine.

[14]  H. Cann,et al.  A national DNA bank in The Gambia, West Africa, and genomic research in developing countries , 2004, Nature Genetics.

[15]  G. Kearns,et al.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.

[16]  M. Feldman,et al.  Genetic Structure of Human Populations , 2002, Science.

[17]  M. Ingelman-Sundberg,et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.

[18]  C. Weinberg,et al.  Evaluation of offspring and maternal genetic effects on disease risk using a family-based approach: the "pent" design. , 2005, American journal of epidemiology.

[19]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[20]  H. Bolt,et al.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. , 1994, The Biochemical journal.

[21]  Paul Wordsworth,et al.  The v‐MFG test: investigating maternal, offspring and maternal‐fetal genetic incompatibility effects on disease and viability , 2006, Genetic epidemiology.

[22]  L. Cavalli-Sforza.  The Human Genome Diversity Project: past, present and future , 2005, Nature Reviews Genetics.

[23]  S. Mallal,et al.  Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[25]  J. Brockmöller,et al.  Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. , 1992, Biochemical pharmacology.